熱門資訊> 正文
Celsion更名为Imunon(IMNN)
2022-09-20 04:43
- Celsion (NASDAQ:CLSN) announced Monday its decision to change company's name to Imunon.
- The new name of clinical-stage drug development company is claimed to outline the "evolution of its business and its commitment to developing cutting-edge immunotherapies and next-generation vaccines to treat cancer and infectious diseases."
- Stock will begin trading under the new ticker symbol "IMNN", effective Sept 21, 2022.
- "With a strong balance sheet supporting current operations into 2025, we are well positioned to build a differentiated company to deliver on the promise of our gene-based therapies," commented Dr. Corinne Le Goff, president and CEO of Imunon.
- Earlier: Celsion says additional data shows placcine vaccine works against COVID-19 in animal model
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
